Novel HDAd/EBV Reprogramming Vector and Highly Efficient Ad/CRISPR-Cas Sickle Cell Disease Gene Correction

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Li, Chao ^a,b   Ding, Lei ^a,b   Sun, Chiao Wang ^a,b   Wu, Li Chen ^a,b   Zhou, Dewang ^a,b   Pawlik, Kevin M ^a,b   Khodadadi Jamayran, Alireza ^b   Westin, Erik ^a,b   Goldman, Frederick D ^b,c   Townes, Tim M ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRIDAE; CELL LINE; CRISPR CAS SYSTEM; EPSTEIN BARR VIRUS; GENE THERAPY; GENE VECTOR; GENETICS; HELPER VIRUS; HOMOZYGOTE; HUMAN; INDUCED PLURIPOTENT STEM CELL; METABOLISM; NUCLEOTIDE SEQUENCE; SICKLE CELL ANEMIA;

ADENOVIRIDAE; ANEMIA, SICKLE CELL; BASE SEQUENCE; CELL LINE; CRISPR-CAS SYSTEMS; GENETIC THERAPY; GENETIC VECTORS; HELPER VIRUSES; HERPESVIRUS 4, HUMAN; HOMOZYGOTE; HUMANS; INDUCED PLURIPOTENT STEM CELLS;

EID: 84979774539     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep30422     Document Type: Article

References (52)

1. Ingram, V. M. A Specific Chemical Difference Between the Globins of Normal Human and Sickle-Cell Anæmia Hæmoglobin. Nature 178, 792-794 (1956).
2. Ingram, V. M. Gene Mutations in Human Hæmoglobin: the Chemical Difference Between Normal and Sickle Cell Hæmoglobin. Nature 180, 326-328 (1957).
3. Thomas, E. D., Blume, K. G. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 5, 341-6 (1999).
4. Takahashi, K., Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-76 (2006).
5. Yu, J. et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science 324, 797-801 (2009).
6. Okita, K. et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 8, 409-12 (2011).
7. Okita, K. et al. An Efficient Non-viral Method to Generate Integration-Free Human iPS Cells from Cord Blood and Peripheral Blood Cells. Stem Cells (2012).
8. Schlaeger, T. M. et al. A comparison of non-integrating reprogramming methods. Nat Biotechnol 33, 58-63 (2015).
9. Tachibana, M. et al. Human embryonic stem cells derived by somatic cell nuclear transfer. Cell 153, 1228-38 (2013).
10. Trounson, A., DeWitt, N. D. Pluripotent stem cells from cloned human embryos: success at long last. Cell Stem Cell 12, 636-8 (2013).
11. Chung, Y. G. et al. Human somatic cell nuclear transfer using adult cells. Cell Stem Cell 14, 777-80 (2014).
12. Yamada, M. et al. Human oocytes reprogram adult somatic nuclei of a type 1 diabetic to diploid pluripotent stem cells. Nature 510, 533-6 (2014).
13. Tsubooka, N. et al. Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts. Genes Cells 14, 683-94 (2009).
14. Feng, B. et al. Reprogramming of fibroblasts into induced pluripotent stem cells with orphan nuclear receptor Esrrb. Nat Cell Biol 11, 197-203 (2009).
15. Han, J. et al. Tbx3 improves the germ-line competency of induced pluripotent stem cells. Nature 463, 1096-100 (2010).
16. Zhao, Y. et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 3, 475-9 (2008).
17. Maekawa, M. et al. Direct reprogramming of somatic cells is promoted by maternal transcription factor Glis1. Nature 474, 225-9 (2011).
18. Edel, M. J. et al. Rem2 GTPase maintains survival of human embryonic stem cells as well as enhancing reprogramming by regulating p53 and cyclin D1. Genes Dev 24, 561-73 (2010).
19. Subramanyam, D. et al. Multiple targets of miR-302 and miR-372 promote reprogramming of human fibroblasts to induced pluripotent stem cells. Nat Biotechnol 29, 443-8 (2011).
20. Onder, T. T. et al. Chromatin-modifying enzymes as modulators of reprogramming. Nature 483, 598-602 (2012).
21. Rais, Y. et al. Deterministic direct reprogramming of somatic cells to pluripotency. Nature 502, 65-70 (2013).
22. Li, M. et al. Efficient correction of hemoglobinopathy-causing mutations by homologous recombination in integration-free patient iPSCs. Cell Res 21, 1740-4 (2011).
23. Zou, J., Mali, P., Huang, X., Dowey, S. N., Cheng, L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 118, 4599-608 (2011).
24. Sebastiano, V. et al. In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. Stem Cells 29, 1717-26 (2011).
25. Yan, W., Smith, C., Cheng, L. Expanded activity of dimer nucleases by combining ZFN and TALEN for genome editing. Sci Rep 3, 2376 (2013).
26. Huang, X. et al. Production of Gene-Corrected Adult Beta Globin Protein in Human Erythrocytes Differentiated from Patient iPSCs After Genome Editing of the Sickle Point Mutation. Stem Cells 33, 1470-9 (2015).
27. Miyaoka, Y. et al. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat Methods 11, 291-3 (2014).
28. Kochanek, S. et al. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 93, 5731-6 (1996).
29. Parks, R. J. et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 93, 13565-70 (1996).
30. Morsy, M. A. et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 95, 7866-71 (1998).
31. Morral, N. et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for longterm liver-directed gene transfer in baboons. Proc Natl Acad Sci USA 96, 12816-21 (1999).
32. Ehrhardt, A., Kay, M. A. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 99, 3923-30 (2002).
33. Kreppel, F., Kochanek, S. Long-term transgene expression in proliferating cells mediated by episomally maintained high-capacity adenovirus vectors. J Virol 78, 9-22 (2004).
34. Dorigo, O. et al. Development of a novel helper-dependent adenovirus-Epstein-Barr virus hybrid system for the stable transformation of mammalian cells. J Virol 78, 6556-66 (2004).
35. Gallaher, S. D., Gil, J. S., Dorigo, O., Berk, A. J. Robust in vivo transduction of a genetically stable Epstein-Barr virus episome to hepatocytes in mice by a hybrid viral vector. J Virol 83, 3249-57 (2009).
36. Gil, J. S., Gallaher, S. D., Berk, A. J. Delivery of an EBV episome by a self-circularizing helper-dependent adenovirus: long-term transgene expression in immunocompetent mice. Gene Ther 17, 1288-93 (2010).
37. Chang, C. W. et al. Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 27, 1042-9 (2009).
38. Mali, P. et al. Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. Stem Cells 28, 713-20 (2010).
39. Aasen, T. et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26, 1276-84 (2008).
40. Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol (2013).
41. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-9 (2013).
42. Hoban, M. D. et al. Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells. Blood 125, 2597-604 (2015).
43. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat Biotechnol 31, 822-6 (2013).
44. Smith, C. et al. Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15, 12-3 (2014).
45. Veres, A. et al. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15, 27-30 (2014).
46. Rice, P., Longden, I., Bleasby, A. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet 16, 276-7 (2000).
47. Holkers, M. et al. Adenoviral vector DNA for accurate genome editing with engineered nucleases. Nat Methods 11, 1051-7 (2014).
48. Suzuki, K. et al. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell 15, 31-6 (2014).
49. Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M., Joung, J. K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat Biotechnol 32, 279-84 (2014).
50. Palmer, D., Ng, P. Improved system for helper-dependent adenoviral vector production. Mol Ther 8, 846-52 (2003).
51. Wu, L. C. et al. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 108, 1183-8 (2006).
52. Chang, C. W. et al. Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting. Cell Rep 12, 1668-77 (2015).